DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Montellano, P. R. O.
Right arrow Articles by Gerber, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Montellano, P. R. O.
Right arrow Articles by Gerber, N.

Vol. 26, Issue 12, 1185-1189, December 1998

Nitric Oxide Synthase Structure and Electron Transfer

Paul R. Ortiz de Montellano, Clinton Nishida, Ignacio Rodriguez-Crespo, and Nancy Gerber

Department of Pharmaceutical Chemistry, University of California, San Francisco

The nitric oxide synthases (NOS), although unrelated to the cytochromes P450 in terms of sequence, exhibit spectroscopic and catalytic properties strongly reminiscent of those of the P450 system. One important difference is the requirement of the NOS enzymes for tetrahydrobiopterin. The biopterin cofactor is shown by chemical studies to bind close to pyrrole ring D of the prosthetic heme group, a position confirmed recently for inducible NOS and endothelial NOS by crystal structures. The only plausible role so far for the tetrahydrobiopterin is as a transient electron donor for the activation of molecular oxygen. NADPH-derived electrons are provided to the heme by the NOS flavin domain, but the biopterin may be required to provide an electron at a faster rate than that supported by the flavin groups. Chimeras in which the reductase domains of the isoforms have been exchanged indicate that the overall rate of catalytic turnover is directly governed by the ability of the flavin domain to deliver electrons. Electron transfer from the flavin to the heme domain, and within the flavin and heme domains, is thus a critical determinant of the catalytic turnover of NOS.

Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
M. Tiso, A. Strub, C. Hesslinger, C. T. Kenney, R. Boer, and D. J. Stuehr
BYK191023 (2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine) Is an NADPH- and Time-Dependent Irreversible Inhibitor of Inducible Nitric-Oxide Synthase
Mol. Pharmacol., April 1, 2008; 73(4): 1244 - 1253.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Tiso, D. W. Konas, K. Panda, E. D. Garcin, M. Sharma, E. D. Getzoff, and D. J. Stuehr
C-terminal Tail Residue Arg1400 Enables NADPH to Regulate Electron Transfer in Neuronal Nitric-oxide Synthase
J. Biol. Chem., November 25, 2005; 280(47): 39208 - 39219.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. I. Lin, D. Fulton, R. Babbitt, I. Fleming, R. Busse, K. A. Pritchard Jr., and W. C. Sessa
Phosphorylation of Threonine 497 in Endothelial Nitric-oxide Synthase Coordinates the Coupling of L-Arginine Metabolism to Efficient Nitric Oxide Production
J. Biol. Chem., November 7, 2003; 278(45): 44719 - 44726.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Vasquez-Vivar, N. Hogg, P. Martasek, H. Karoui, K. A. Pritchard Jr., and B. Kalyanaraman
Tetrahydrobiopterin-dependent Inhibition of Superoxide Generation from Neuronal Nitric Oxide Synthase
J. Biol. Chem., September 17, 1999; 274(38): 26736 - 26742.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1998 by the American Society for Pharmacology and Experimental Therapeutics.